Renaissance Technologies LLC boosted its position in shares of Kamada Ltd. (NASDAQ:KMDA) by 16.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 264,800 shares of the biotechnology company’s stock after buying an additional 37,800 shares during the period. Renaissance Technologies LLC owned 0.73% of Kamada worth $1,801,000 as of its most recent filing with the SEC.
Separately, Norges Bank bought a new position in Kamada during the fourth quarter valued at about $377,000. 5.73% of the stock is currently owned by institutional investors and hedge funds.
Kamada Ltd. (NASDAQ KMDA) traded down 0.3814% on Monday, hitting $4.2836. The stock had a trading volume of 37,084 shares. Kamada Ltd. has a 12-month low of $3.75 and a 12-month high of $8.61. The company has a 50 day moving average of $5.15 and a 200 day moving average of $6.56. The company’s market capitalization is $160.21 million.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Kamada had a negative net margin of 2.24% and a negative return on equity of 2.94%. The company had revenue of $32.55 million during the quarter, compared to the consensus estimate of $33.30 million. During the same period in the previous year, the firm posted ($0.04) EPS. The firm’s revenue was up 70.7% compared to the same quarter last year. On average, equities analysts expect that Kamada Ltd. will post $0.06 earnings per share for the current year.
Several research analysts have recently issued reports on the company. Jefferies Group LLC restated a “buy” rating and issued a $9.00 price target on shares of Kamada in a research report on Wednesday, May 17th. Zacks Investment Research lowered Kamada from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, TheStreet lowered Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
